"While covering these drugs may serve employees' needs and potentially increase satisfaction with their employee benefits package ... many employers hesitate to offer new coverage from a cost perspective alone. A 2025 article ... reports a notable increase in the average representation of GLP-1 drugs used for weight loss in total annual claims for employers, increasing from 8.9 percent in 2024 to 10.5 percent in 2025. Overall, 36 percent of employers are providing GLP-1 coverage for both diabetes and weight loss (up from 34 percent in 2024)."  MORE >>